The polycomb group gene MEL-18 may prevent trastuzumab resistance making it a potential novel biomarker for HER2+ breast cancer. Journal of the National Cancer Institute
Original Article: MEL-18 Amplification in Anti-HER2 Therapy of Breast Cancer